# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-096189
Filing Date
2024-08-13
Accepted
2024-08-13 16:08:22
Documents
74
Period of Report
2024-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | krro-20240630.htm iXBRL | 10-Q | 2324788
2 | EX-31.1 | krro-ex31_1.htm | EX-31.1 | 17331
3 | EX-31.2 | krro-ex31_2.htm | EX-31.2 | 17213
4 | EX-32.1 | krro-ex32_1.htm | EX-32.1 | 9447
| Complete submission text file | 0000950170-24-096189.txt |  | 8405412

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | krro-20240630.xsd | EX-101.SCH | 1395617
76 | EXTRACTED XBRL INSTANCE DOCUMENT | krro-20240630_htm.xml | XML | 1141964

Mailing Address ONE KENDALL SQUARE. BUILDING 600-700 SUITE 6-401 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE. BUILDING 600-700 SUITE 6-401 CAMBRIDGE MA 02139 617-468-1999
Korro Bio, Inc. (Filer) CIK: 0001703647 (see all company filings)

EIN.: 472324450 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39062 | Film No.: 241201450
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)